Understand the source comparison
SS-31 for Mitochondrial Function: Research Design Comparison
Cardiac ischemia-reperfusion 3–5 mg/kg IV bolus pre-reperfusion Infarct size, troponin release, LVEF, mitochondrial ΔΨm Cardiolipin stabilization prevents cytochrome c release and reduces ROS burst during reperfusion 24–72 hours (acute protection) Gold standar
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cardiac ischemia-reperfusion
- 3–5 mg/kg IV bolus pre-reperfusion
- Infarct size, troponin release, LVEF, mitochondrial ΔΨm
- Cardiolipin stabilization prevents cytochrome c release and reduces ROS burst during reperfusion
- 24–72 hours (acute protection)
- Gold standard for acute cardioprotection studies; IV timing is critical. Must be administered before or within 15 min of reperfusion
- Heart failure (chronic)
- 1–4 mg/kg/day SC for 4–12 weeks
- Peak VO2, 6MWT distance, diastolic function (E/e' ratio), LV remodeling
- Preserves cristae structure and ETC efficiency, improving ATP/O2 ratio in failing cardiomyocytes
- 4–8 weeks (functional improvement)
- Best outcomes in HFpEF models; combine with echocardiography and cardiopulmonary exercise testing for mechanistic clarity
- Parkinson's disease (MPTP model)
- 0.5–1.0 mg/kg/day IP for 7–21 days
- Striatal dopamine content, motor coordination (rotarod), TH+ neuron count
- Prevents bioenergetic collapse in dopaminergic neurons by maintaining Complex I activity
- 7–14 days (neuroprotection)
- Co-administration with neurotoxin required for protection studies; post-lesion treatment shows minimal effect (prevention > rescue)
- Type 2 diabetes / insulin resistance
- 1–3 mg/kg/day SC for 4–12 weeks
- Fasting glucose, insulin sensitivity index (HOMA-IR), mitochondrial respiration (Seahorse assay)
- Restores skeletal muscle fatty acid oxidation by improving ETC coupling and reducing electron leak
- 4–6 weeks (metabolic shift)
- Pair with hyperinsulinemic-euglycemic clamp for rigorous insulin sensitivity measurement; muscle biopsy recommended for direct mitochondrial function assessment
- Acute kidney injury
- 2.5–5 mg/kg IV bolus or continuous infusion
- Serum creatinine, tubular necrosis score, mitochondrial swelling (EM), ATP content
- Prevents mitochondrial permeability transition pore (mPTP) opening and preserves tubular cell ATP during ischemic insult
- 6–24 hours (renal protection)
- Most effective when administered during ischemic period or within 1 hour of reperfusion; longer delays reduce efficacy significantly
- Aging / sarcopenia
- 1–3 mg/kg/day SC for 8–16 weeks
- Grip strength, rotarod endurance, muscle fiber CSA, mitochondrial H2O2 emission
- Reduces age-related cardiolipin peroxidation, restoring state 3 respiration and lowering ROS production in aged muscle
- 8–12 weeks (functional gains)
- Aging studies require longer timelines; combine with exercise intervention to assess whether SS-31 enhances training adaptation or acts independently